<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dry eye disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dry eye disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dry eye disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roni M Shtein, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah S Jacobs, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Dry eye disease (DED) is a multifactorial disease of the ocular surface with loss of homeostasis of the tear film and ocular symptoms. Tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles [<a href="#rid1">1</a>]. DED is also known as keratoconjunctivitis sicca, dry eye syndrome, and dysfunctional tear syndrome.</p><p>The epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment options for DED will be reviewed here. Various conditions associated with DED are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a> and  <a class="medical medical_review" href="/z/d/html/5547.html" rel="external">"Allergic conjunctivitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6915.html" rel="external">"Blepharitis"</a> and  <a class="medical medical_review" href="/z/d/html/6900.html" rel="external">"The red eye: Evaluation and management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>In epidemiological studies performed globally, the prevalence of dry eye disease (DED) ranges from 5 to 50 percent [<a href="#rid2">2</a>].</p><p>Based on data from the National Health and Wellness Survey, 6.8 percent of the United States adult population (approximately 16.4 million people) have been diagnosed with DED [<a href="#rid3">3</a>]. The prevalence increased with age (2.7 percent in those 18 to 34 years old versus 18.6 percent in those ≥75 years old) and was higher in women than men (8.8 versus 4.5 percent). Prevalence was not affected by education or location of residence. A 2022 meta-analysis of three United States studies estimated a pooled prevalence of dry eye of 8.1 percent [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Risk factors for DED include [<a href="#rid5">5-9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced age</p><p class="bulletIndent1"><span class="glyph">●</span>Female sex</p><p class="bulletIndent1"><span class="glyph">●</span>Hormonal changes (primarily due to decreased androgens)</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic diseases (eg, diabetes mellitus, Parkinson disease, Sjögren's disease)</p><p class="bulletIndent1"><span class="glyph">●</span>Contact lens wear</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic medications (antihistamines, anticholinergics, estrogens, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>, selective serotonin receptor antagonists, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, nicotinic acid)</p><p class="bulletIndent1"><span class="glyph">●</span>Ocular medications (especially those containing preservatives)</p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional deficiencies (eg, vitamin A deficiency)</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased corneal sensation</p><p class="bulletIndent1"><span class="glyph">●</span>Ophthalmic surgery (especially corneal refractive surgery)</p><p class="bulletIndent1"><span class="glyph">●</span>Low-humidity environments</p><p></p><p>Studies of the global burden of DED report that persons living in Asia (principally China, Tibet, Korea) have a higher prevalence [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL SIGNIFICANCE</span><span class="headingEndMark"> — </span>Dry eye disease (DED), particularly when severe, can have a significant impact on visual acuity, daily activities, social and physical functioning, and workplace productivity [<a href="#rid10">10-12</a>].</p><p>In addition, patients with DED incur direct medical costs through frequent visits to health care professionals as well as pharmacologic and nonpharmacologic therapies. Indirect costs include decreased productivity and time lost from work [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Dry eye disease (DED) has a complex and multifactorial etiology. The tear film of the eye consists of aqueous, mucous, and lipid components . A healthy tear film relies on a synergistic interaction of the lacrimal glands, eyelids, and ocular surface, which together comprise the lacrimal functional unit  (<a class="graphic graphic_figure graphicRef64230" href="/z/d/graphic/64230.html" rel="external">figure 1</a>) [<a href="#rid14">14</a>]. Dysfunction of any component in the lacrimal functional unit can lead to DED.</p><p>Historically, DED has been classified into two general groups: decreased tear production (resulting in aqueous deficient DED) and abnormal meibomian gland physiology (resulting in evaporative DED). However, it is now believed that both mechanisms are present in most patients, although one may be predominant [<a href="#rid1">1</a>]. For all patients, tear film hyperosmolarity and subsequent ocular surface inflammation lead to the variety of symptoms and signs associated with DED.</p><p>Symptoms in DED result from activation of sensory nerves of the ocular surface, either due to tear hyperosmolarity, the presence of inflammatory mediators, or hypersensitivity of the sensory nerves [<a href="#rid15">15,16</a>]. (See <a class="local">'Symptoms'</a> below.)</p><p class="headingAnchor" id="H1875271138"><span class="h1">CAUSES</span></p><p class="headingAnchor" id="H7"><span class="h2">Decreased tear production</span><span class="headingEndMark"> — </span>Impaired lacrimal tear production can be caused by any form of lacrimal gland destruction or dysfunction. The reduced volume of aqueous fluid leads to hyperosmolarity of the tear film and subsequently the ocular surface, which incites inflammation of the ocular surface cells [<a href="#rid17">17</a>].</p><p>Deficiency of aqueous tear production can be subclassified into two main subtypes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sjögren's disease</strong> – Sjögren's disease is a chronic autoimmune inflammatory disorder characterized by diminished lacrimal and salivary gland function with resultant dryness of the eyes and mouth. The onset of Sjögren's disease is rare after age 65 years [<a href="#rid18">18</a>]. DED related to Sjögren's disease is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a> and  <a class="medical medical_review" href="/z/d/html/5607.html" rel="external">"Clinical manifestations of Sjögren's disease: Exocrine gland disease", section on 'Dry eye'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dry eye syndrome not due to Sjögren's disease</strong> – This disease refers to patients with aqueous tear-deficient DED involving lacrimal dysfunction without associated systemic findings. The most common form is age-related DED in which it is believed that there is lacrimal ductal obstruction over time, leading to decreased lacrimal gland function [<a href="#rid19">19</a>]. Lacrimal gland obstruction can also be due to conjunctival scarring conditions such as trachoma, pemphigoid, vitamin deficiency, post-viral syndromes, and ocular burns [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/3026.html" rel="external">"Trachoma"</a>.)</p><p></p><p class="bulletIndent1">This disease can also be caused by lacrimal gland infiltration due to sarcoidosis, lymphoma, graft versus host disease, and episcleritis. Other causes include contact lens use, which is associated with reduced corneal sensitivity and subsequent reduced reflex sensory tear secretion [<a href="#rid21">21</a>], and diabetes mellitus [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/6913.html" rel="external">"Complications of contact lenses"</a> and  <a class="medical medical_review" href="/z/d/html/5610.html" rel="external">"Episcleritis"</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Increased evaporative loss</span><span class="headingEndMark"> — </span>Excessive water loss from the ocular surface leads to tear film instability and a cycle of tear hyperosmolarity and lacrimal functional unit inflammation. Increased tear evaporation is most commonly caused by meibomian gland dysfunction, also known as posterior blepharitis, in which the accessory lacrimal glands responsible for the lipid component of the tear film are dysfunctional [<a href="#rid20">20</a>]. In a normally functioning eye, the nature of the mucin allows even spreading of the tear film to form a membrane, and the lipid layer provides a barrier to minimize evaporation of tears [<a href="#rid23">23</a>]. Abnormalities of the lipid layer are associated with a higher rate of tear film evaporation [<a href="#rid24">24</a>].</p><p>Structural abnormalities of eyelid position or decreased blink function also increase evaporation of the tear film by increasing the area or the time of tear film exposure [<a href="#rid20">20,25</a>]. Lastly, topical medicated or preserved eye drop use, chronic contact lens wear, and ocular allergy syndromes can cause ocular surface irritation and increased tear film evaporation [<a href="#rid20">20,25</a>].</p><p class="headingAnchor" id="H11"><span class="h1">SYMPTOMS</span><span class="headingEndMark"> — </span>Most patients will present with symptoms of chronic eye irritation associated with mild to moderate discomfort [<a href="#rid26">26</a>]. However, there is considerable variability in patient-reported symptoms and clinically measurable signs over time, as well as a recognized lack of correlation between these symptoms and signs [<a href="#rid25">25,27-29</a>].</p><p>Common eye complaints include:</p><p class="bulletIndent1"><span class="glyph">●</span>Dryness</p><p class="bulletIndent1"><span class="glyph">●</span>Red eyes</p><p class="bulletIndent1"><span class="glyph">●</span>General irritation</p><p class="bulletIndent1"><span class="glyph">●</span>Gritty sensation</p><p class="bulletIndent1"><span class="glyph">●</span>Burning sensation</p><p class="bulletIndent1"><span class="glyph">●</span>Foreign body sensation</p><p class="bulletIndent1"><span class="glyph">●</span>Paradoxical excessive tearing </p><p class="bulletIndent1"><span class="glyph">●</span>Light sensitivity</p><p class="bulletIndent1"><span class="glyph">●</span>Blurred vision</p><p></p><p>Inciting or exacerbating causes include medications, windy conditions, cold weather, low-humidity environment, extended time spent looking at screens, and time of day.</p><p>The blurred vision associated with DED tends to be quite variable. Since the tear film is the first layer encountered by light rays as they enter the eye, an irregular tear film can degrade the quality of the image that is received by the retina. The visual impairment associated with DED is usually temporary and often improves with treatment of the condition [<a href="#rid30">30,31</a>]. Rarely, in severe DED conditions, permanent damage to visual acuity can occur from corneal scarring or ulceration.</p><p>If ocular complaints are accompanied by mouth dryness and other systemic complaints, an evaluation for Sjögren's disease should be performed. (See  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a>.)</p><p class="headingAnchor" id="H3145911381"><span class="h2">Questionnaires</span><span class="headingEndMark"> — </span>Due to the variability of findings on clinical evaluation of dry eye disease (DED), some clinicians base their assessment of DED on the results of validated questionnaires [<a href="#rid32">32</a>]. These can also be used for monitoring DED and can be useful for standardizing the identification and classification of DED [<a href="#rid33">33</a>].</p><p>Some of the more widely available questionnaires that are used specifically for the evaluation of DED symptoms include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ocular Surface Disease Index (OSDI) – Twelve-item questionnaire validated in patients with DED [<a href="#rid34">34</a>]. The OSDI can be useful clinically, particularly in patients with more severe symptoms, to monitor the response to therapy and variability in symptoms over time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dry Eye Questionnaire (DEQ-5) – Five-item questionnaire reduced from the Dry Eye Questionnaire and validated to determine DED symptom severity [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impact of Dry Eye on Everyday Life (IDEEL) – Fifty-seven questions in three modules validated in patients with DED [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Salisbury Eye Evaluation Questionnaire (SEE) – Six-item questionnaire used in self-reported, population-based prevalence surveys to determine visual impairment among older adult subjects [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of dry eye disease (DED) is based on characteristic patient symptoms and supporting findings on the physical examination, both of which can vary considerably in intensity over time and under different environmental conditions. Potential supportive findings on physical examination include:</p><p class="bulletIndent1"><span class="glyph">●</span>Conjunctival injection, usually symmetric in both eyes  (<a class="graphic graphic_picture graphicRef72833" href="/z/d/graphic/72833.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breakdown of ocular surface, and corneal scarring  (<a class="graphic graphic_picture graphicRef62824 graphicRef75685" href="/z/d/graphic/62824.html" rel="external">picture 2A-B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Excessive reflex tearing from irritation due to dryness, which can paradoxically be a sign of DED.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blepharitis, often visible as erythematous or irritated eyelid edges  (<a class="graphic graphic_picture graphicRef64540 graphicRef61924" href="/z/d/graphic/64540.html" rel="external">picture 3A-B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malposition of the eyelids (inward or outward turning, also called entropion and ectropion, respectively)  (<a class="graphic graphic_picture graphicRef63579" href="/z/d/graphic/63579.html" rel="external">picture 4</a> and <a class="graphic graphic_picture graphicRef72737" href="/z/d/graphic/72737.html" rel="external">picture 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced blink rate. Normal blink rate varies by environment and activity but is generally in the range of 5 to 26 blinks per minute [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Visual impairment, with visual acuity assessed in each eye separately. This should include evaluation as to whether acuity improves with increased blink rate or use of lubricating eye drops.</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Differential diagnosis and coexisting conditions</span><span class="headingEndMark"> — </span>Other conditions that can cause similar symptoms to DED include:</p><p class="bulletIndent1"><span class="glyph">●</span>Viral conjunctivitis – DED can be confused with "pink eye." A careful patient history to elicit course of recent and abrupt onset of symptoms, any recent illnesses or sick contacts, and presence of lymphadenopathy can help to distinguish the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/6907.html" rel="external">"Conjunctivitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other microbial infections – Some ocular infections can begin with an indolent course of symptoms similar to DED. Referral to an ophthalmologist should be considered for any patients at high risk for ocular infections (eg, contact lens wearer, history of diabetes mellitus), particularly those with signs of an infectious process on physical examination (eg, unilateral conjunctival injection, purulent drainage).</p><p></p><p>Coexisting disorders include:</p><p class="bulletIndent1"><span class="glyph">●</span>Blepharitis/Meibomian gland dysfunction – Posterior blepharitis often coexists with DED and may require specific treatments, including warm compresses and patient education on eyelid hygiene. (See  <a class="medical medical_review" href="/z/d/html/6915.html" rel="external">"Blepharitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ocular allergies – Allergic conjunctivitis can also coexist with DED. Symptoms of itching will often be the primary complaint. The allergen should be promptly identified and avoided. (See  <a class="medical medical_review" href="/z/d/html/5547.html" rel="external">"Allergic conjunctivitis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">INITIAL TREATMENT</span><span class="headingEndMark"> — </span>Treatment for dry eye disease (DED) is aimed at improving symptoms by increasing or supplementing tear production, slowing tear evaporation, reducing tear resorption, or reducing ocular surface inflammation. In addition to symptomatic relief, treatment with <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">artificial tears</a> may improve visual acuity and prevent against ocular damage [<a href="#rid8">8,39,40</a>].</p><p class="headingAnchor" id="H3581536532"><span class="h2">First line treatments</span><span class="headingEndMark"> — </span>The first line of treatment in patients complaining of DED are:</p><p class="bulletIndent1"><span class="glyph">●</span>Tear supplementation</p><p class="bulletIndent1"><span class="glyph">●</span>Environmental coping strategies</p><p class="bulletIndent1"><span class="glyph">●</span>Amelioration of eyelid abnormalities including blepharitis (see  <a class="medical medical_review" href="/z/d/html/6915.html" rel="external">"Blepharitis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Application of warm compresses (to soften secretions in obstructed meibomian gland excretory ducts)</p><p class="bulletIndent1"><span class="glyph">●</span>Discontinuation of systemic or ocular medications that can contribute to dryness, if possible (see <a class="local">'Risk factors'</a> above)</p><p></p><p>Patients who do not obtain adequate relief from tear supplementation or environmental adjustment should be referred to an ophthalmologist.</p><p class="headingAnchor" id="H17"><span class="h3">Artificial tears</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">Artificial tears</a> generally include cellulose to maintain viscosity, a spreading agent such as polyethylene glycol or polyvinyl alcohol to prevent evaporation, and a preservative to prevent contamination. Available without a prescription, artificial tears come in liquid, gel, and ointment forms. Preservative-free forms of these supplements are often recommended as some individuals with DED will have inflammatory reactions to the preservatives [<a href="#rid41">41</a>]. However, these are often expensive, single-use formulations.</p><p>In February of 2023, the Centers for Disease Control and Prevention (CDC) recommended discontinuation of use of over-the-counter EzriCare <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">Artificial Tears</a> due to an outbreak of extensively drug-resistant <em>Pseudomonas aeruginosa</em> associated with that product [<a href="#rid42">42</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drops</strong> – A reasonable starting dose is one drop in each eye, four times per day. Patients often begin to notice improvement within a few days of initiating treatment but may take up to three to four weeks to note a significant change in their symptoms. Some patients may benefit from viewing an online video (eg, YouTube) for a demonstration of eyedrop administration methods.</p><p></p><p class="bulletIndent1">If individuals remain symptomatic, the frequency can be increased to as frequently as every hour. If used more often than four to six times per day, a preservative-free formulation is preferable to minimize the potential for toxicity [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gels and ointments</strong> – Higher-viscosity artificial tear gels and ointments are also commercially available and can be used if patients feel that the eye drops are not providing enough symptomatic relief. Patients should be warned that the gels, and especially ointments, can blur vision temporarily and are often best used at bedtime.</p><p></p><p>Response to therapy can be monitored subjectively or with standardized questionnaires (see <a class="local">'Questionnaires'</a> above). Chronic treatment is usually needed, unless a specific inciting factor can be eliminated.</p><p>Randomized trials of efficacy are mostly limited due to sample size, lack of an adequate control group, lack of clear diagnostic criteria, and non-standardized outcomes [<a href="#rid44">44-47</a>]. As laser-assisted in situ keratomileusis (LASIK) is a refractive procedure that causes dry eyes, in part due to decreased postoperative corneal sensation, LASIK serves as a model for assessing treatment of DED. <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">Artificial tears</a> given to postoperative LASIK patients appear to improve DED symptoms compared with placebo [<a href="#rid48">48</a>]. Issues related to DED and LASIK are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6908.html" rel="external">"Laser refractive surgery"</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Environmental strategies</span><span class="headingEndMark"> — </span>Environmental coping strategies address the importance of environmental causes that could be contributing to or even causing DED symptoms. One important strategy includes frequent blinking, especially during visually attentive tasks such as reading or computer use. The patient should also be urged to minimize exposure to air conditioning or heating. Humidifiers are useful in the bedroom, office, or any space where the patient spends a significant amount of time.</p><p>Physical barriers around the eyes or "moisture chambers" are recommended to protect the humidity of the local environment around the eyes. Moisture chambers can be purchased and fitted to current glasses in select optical shops by trained opticians  (<a class="graphic graphic_picture graphicRef75764 graphicRef52738" href="/z/d/graphic/75764.html" rel="external">picture 6A-B</a>).</p><p class="headingAnchor" id="H3670194309"><span class="h2">Indications for referral</span><span class="headingEndMark"> — </span>In most patients, first-line treatment can be initiated by the primary care provider. However, initial referral to an ophthalmologist is appropriate for patients with neuropathy (including diabetic neuropathy), as they may have reduced sensation and be unaware of severe dryness, which may cause visual disturbance or ocular surface damage if not treated. We also suggest initial referral to an ophthalmologist if the diagnosis is in question or if the patient has severe pain or associated visual loss, or abnormal blinking or inability to close their eyes completely [<a href="#rid49">49</a>]. (See <a class="local">'Ophthalmology evaluation and treatment'</a> below.)</p><p class="headingAnchor" id="H2068529813"><span class="h1">OPHTHALMOLOGY EVALUATION AND TREATMENT</span></p><p class="headingAnchor" id="H1329709196"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>The ophthalmologist will perform a thorough slit lamp examination along with other testing to assess the status of the patient's lacrimal functional unit to determine the severity of dry eye disease (DED) and possible etiologies. Evaluation includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Extent and pattern of conjunctival injection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eyelid health – Any eyelid or punctal malpositions are noted as they can lead to DED and often can be surgically repaired. Careful evaluation for meibomian gland dysfunction (posterior blepharitis) is performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ocular surface staining – <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">Fluorescein</a> is used to stain for areas of discontinuity in the epithelial surface of the cornea  (<a class="graphic graphic_picture graphicRef75497" href="/z/d/graphic/75497.html" rel="external">picture 7</a>). Lissamine green and Rose Bengal are used to stain areas of devitalized epithelium in the cornea and conjunctiva.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tear break-up time – Measured with <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> stain in the eye to determine tear film stability. The patient is instructed not to blink and the tear film is observed through the slit lamp. If the smooth, stained green tear film layer begins to develop blue gaps in less than 10 seconds, the patient's tear film is considered abnormal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Schirmer test – Assessed by quantifying the number of tears produced by each eye. Small strips of filter paper are placed in the lower eyelids of each eye, either with or without prior instillation of anesthetic eye drops. Results are measured in millimeters of tears collected over a five-minute time period. This test is often used in the clinical setting but provides extremely variable results [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Corneal sensation – Objectively measured with a variety of techniques to provide information about ocular surface and possibly systemic associations of DED.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tear hyperosmolarity [<a href="#rid50">50,51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ocular surface inflammation (eg, matrix metalloproteinase 9 as a marker of ocular surface inflammation) [<a href="#rid52">52,53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tear film measurements – In-office imaging instruments can be used to more objectively measure the ocular surface and the tear film, including tear meniscus height, tear film stability, blink dynamics, and meibography of the eyelids.</p><p></p><p class="headingAnchor" id="H4004903825"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The choice of topical treatments is usually guided by medication cost and insurance coverage.</p><p class="headingAnchor" id="H19"><span class="h3">Topical cyclosporine</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is a safe and well-tolerated immunosuppressive agent, although it is not clear that it leads to a clinically important benefit in the treatment of DED [<a href="#rid54">54-56</a>]. The multiple randomized trials of topical cyclosporine indicating its efficacy vary greatly by dose of cyclosporine, the comparator control used (ie, active comparator or no treatment), and the endpoint reported; thus, the degree of benefit afforded by use of this agent remains uncertain.</p><p>Although not universally beneficial, there appears to be a subset of patients who do respond favorably to this treatment, but there are no good predictive models available to guide clinical decision-making. In the author’s anecdotal experience, patients with a systemic condition associated with inflammation, including graft-versus-host disease, tend to have the highest likelihood of response to <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> drops [<a href="#rid57">57</a>].</p><p>In such patients, a 0.05% emulsion a 0.09% and a 0.1% solution of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> are available for treatment of DED. It may take up to six weeks or longer of treatment to achieve noticeable improvement of dryness. In some patients, cyclosporine can result in long-term resolution of DED symptoms, as shown in one case series describing eight such patients, five of whom represented about four percent of all cyclosporine-treated patients with chronic DED in one clinical practice [<a href="#rid58">58</a>].</p><p>Serum <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> concentrations have been undetectable or negligible with topical use, and no systemic toxicity has been reported. Cyclosporine can cause an occasional, temporary burning sensation in the eye [<a href="#rid39">39</a>].</p><p>As patients may have other concurrent problems such as infection leading to eye irritation, they should have a complete ophthalmological examination prior to receiving <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>.</p><p class="headingAnchor" id="H1212621937"><span class="h3">Topical lifitegrast</span><span class="headingEndMark"> — </span>A topical eye drop formulation, <a class="drug drug_general" data-topicid="109082" href="/z/d/drug information/109082.html" rel="external">lifitegrast</a> 5%, an integrin antagonist, is used twice a day and has side effects of eye irritation or discomfort and an associated bad taste in approximately 25 percent of users [<a href="#rid59">59</a>]. In randomized trials, lifitegrast improved DED signs and symptoms in patients with mild to moderate and moderate to severe symptoms [<a href="#rid59">59-63</a>].</p><p>The prescription and monitoring of response to this agent should be done by an ophthalmologist.</p><p class="headingAnchor" id="H2549096944"><span class="h3">Intranasal varenicline</span><span class="headingEndMark"> — </span>A preservative-free nasal spray formulation of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, a nicotinic acetylcholine receptor agonist, has been approved by the US Food and Drug Administration (FDA) for the treatment of dry eyes. The suspected mechanism of action is by activating the trigeminal parasympathetic pathway to stimulate natural tear production. In a trial conducted among adults with DED, varenicline use resulted in an increase in tear production, as measured by Schirmer test, after four weeks of twice-daily dosing compared with placebo (vehicle) [<a href="#rid64">64</a>]. The most common reported adverse events were sneezing, cough, and throat irritation.</p><p class="headingAnchor" id="H1686699403"><span class="h3">Perfluorohexyloctane</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="141560" href="/z/d/drug information/141560.html" rel="external">Perfluorohexyloctane</a> eye drops are available as a tear substitute (FDA approved in the United States in 2023). They have been found to help improve both the signs and symptoms of dry eye disease [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Other</span><span class="headingEndMark"> — </span>Although several other treatments are available for DED, they are not in common use and should only be used as an adjunctive treatment by eye specialists.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical glucocorticoids</strong> – Low-dose topical glucocorticoid eye drops can help to relieve symptoms and signs of DED [<a href="#rid66">66,67</a>] and are useful on a short-term basis. As these drops can have significant side effects with continued use, including cataracts and glaucoma, glucocorticoid eye drops should be used with caution and only be prescribed by an ophthalmologist for this indication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Punctal occlusion</strong> – Either temporary punctal plugs or permanent cauterization of the puncta can be performed in an attempt to reduce the rate of tear drainage from the ocular surface and thereby possibly improve the signs and symptoms of DED [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous serum tears</strong> – The serum of a patient's blood can be formulated into eye drops. Autologous serum tears may improve DED symptoms [<a href="#rid69">69,70</a>], but there is not strong evidence for long-term or significant benefit over <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">artificial tears</a> [<a href="#rid71">71</a>]. Access to these eye drops and cost are barriers to its use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tear stimulation</strong> – Systemic <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a> (a cholinergic agonist) has been found to improve DED symptoms in patients, most commonly those with Sjögren's disease, but is associated with systemic side effects in a significant portion of patients [<a href="#rid72">72</a>]. Other tear stimulation agents, including those for topical use, are being explored as potential treatments for DED [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Omega-3 fatty acids</strong> – Trials of oral omega-3 fatty acids for DED have shown mixed results, with a large multicenter clinical trial showing no additional benefit of omega-3 fatty acid supplementation over placebo in the improvement of DED signs and symptoms [<a href="#rid74">74-78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral antioxidants</strong> – Small randomized trials have shown some efficacy of oral antioxidants in the treatment of DED [<a href="#rid79">79,80</a>]. As an example, in a blinded, placebo-controlled cross-over trial of 24 DED patients, those randomly assigned an antioxidant combination (vitamins E, B2, C, zinc and <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a>) compared with placebo had improved tear break-up times, Schirmer scores, and clinical symptoms, including burning, itching, and redness [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scleral contact lenses</strong> – In patients with severe DED, large-diameter contact lenses can be used to help retain a tear reservoir over the ocular surface [<a href="#rid81">81</a>]. These types of contact lenses require a specialized fitting by an experienced contact lens practitioner.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acupuncture</strong> – Small studies have shown some improvement in DED signs and symptoms following acupuncture therapy [<a href="#rid82">82,83</a>]. Acupuncture is discussed in detail separately. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery</strong> – Eyelid abnormalities should be surgically corrected to realign and maintain normal lid architecture. Surgery can also be performed on structurally normal eyelids to reduce the ocular surface area and thus reduce tear evaporation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational</strong> – Diquafosol [<a href="#rid84">84-86</a>] and rebamipide [<a href="#rid87">87-89</a>] eye drops have also shown promise in improving DED.</p><p></p><p class="headingAnchor" id="H108976428"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83060.html" rel="external">"Patient education: Dry eye (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Dry eye disease (DED) is a multifactorial disease of the tears and ocular surface that can result in ocular discomfort and visual impairment. DED is generally due to both decreased tear production and/or excessive evaporative loss. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Most patients present with symptoms of chronic eye irritation, such as eye dryness, red eyes, and burning. However, there is considerable variability in patient-reported symptoms over time. (See <a class="local">'Clinical significance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis is based primarily on patient symptoms and supportive findings of DED from examination. Common findings include conjunctival injection and reduced blink rate. Some patients may have paradoxical excess reflex tearing. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> – We suggest initial treatment with <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">artificial tears</a> for all patients with dry eye disease (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This is particularly important in patients who have reduced ocular sensation, such as those with neuropathy (including diabetic neuropathy), who may be unaware of severe dryness, which may cause visual disturbance or ocular surface damage if not treated. In addition to symptomatic relief, artificial tears may improve visual acuity and prevent against ocular damage.</p><p></p><p class="bulletIndent1">When appropriate, environmental strategies should also be undertaken, including discussing the importance of frequent blinking and minimizing exposure to air conditioning or heating. (See <a class="local">'Initial treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for referral</strong> – Referral to an ophthalmologist is appropriate for patients with neuropathy (including diabetic neuropathy), those in whom the diagnosis is in question, patients with severe pain or associated visual loss, or those with abnormal blinking or inability to close their eyes completely. (See <a class="local">'Indications for referral'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further treatment</strong> – Other treatment options include topical <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, other topical medications, oral medications, scleral contact lenses, punctal occlusion, and surgery. (See <a class="local">'Treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf 2017; 15:276.</a></li><li><a class="nounderline abstract_t">Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf 2017; 15:334.</a></li><li><a class="nounderline abstract_t">Farrand KF, Fridman M, Stillman IÖ, Schaumberg DA. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol 2017; 182:90.</a></li><li><a class="nounderline abstract_t">McCann P, Abraham AG, Mukhopadhyay A, et al. Prevalence and Incidence of Dry Eye and Meibomian Gland Dysfunction in the United States: A Systematic Review and Meta-analysis. JAMA Ophthalmol 2022; 140:1181.</a></li><li><a class="nounderline abstract_t">Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol 2014; 157:799.</a></li><li><a class="nounderline abstract_t">Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications : recognition and management. Drugs 2007; 67:75.</a></li><li><a class="nounderline abstract_t">Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341.</a></li><li><a class="nounderline abstract_t">Gilbard JP. The diagnosis and management of dry eyes. Otolaryngol Clin North Am 2005; 38:871.</a></li><li><a class="nounderline abstract_t">Latkany R. Dry eyes: etiology and management. Curr Opin Ophthalmol 2008; 19:287.</a></li><li><a class="nounderline abstract_t">Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008; 14:S102.</a></li><li><a class="nounderline abstract_t">Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology 2003; 110:1412.</a></li><li><a class="nounderline abstract_t">Buchholz P, Steeds CS, Stern LS, et al. Utility assessment to measure the impact of dry eye disease. Ocul Surf 2006; 4:155.</a></li><li><a class="nounderline abstract_t">Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: a conceptual framework and preliminary assessment. Cornea 2004; 23:751.</a></li><li><a class="nounderline abstract_t">Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998; 17:584.</a></li><li><a class="nounderline abstract_t">Belmonte C, Acosta MC, Gallar J. Neural basis of sensation in intact and injured corneas. Exp Eye Res 2004; 78:513.</a></li><li><a class="nounderline abstract_t">Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Ocul Surf 2017; 15:404.</a></li><li><a class="nounderline abstract_t">Li DQ, Chen Z, Song XJ, et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004; 45:4302.</a></li><li><a class="nounderline abstract_t">Botsios C, Furlan A, Ostuni P, et al. Elderly onset of primary Sjögren's syndrome: clinical manifestations, serological features and oral/ocular diagnostic tests. Comparison with adult and young onset of the disease in a cohort of 336 Italian patients. Joint Bone Spine 2011; 78:171.</a></li><li><a class="nounderline abstract_t">Damato BE, Allan D, Murray SB, Lee WR. Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease. Br J Ophthalmol 1984; 68:674.</a></li><li><a class="nounderline abstract_t">The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:75.</a></li><li><a class="nounderline abstract_t">Gilbard JP, Gray KL, Rossi SR. A proposed mechanism for increased tear-film osmolarity in contact lens wearers. Am J Ophthalmol 1986; 102:505.</a></li><li><a class="nounderline abstract_t">Kaiserman I, Kaiserman N, Nakar S, Vinker S. Dry eye in diabetic patients. Am J Ophthalmol 2005; 139:498.</a></li><li><a class="nounderline abstract_t">Tsubota K. Tear dynamics and dry eye. Prog Retin Eye Res 1998; 17:565.</a></li><li><a class="nounderline abstract_t">Bron AJ, Tiffany JM, Gouveia SM, et al. Functional aspects of the tear film lipid layer. Exp Eye Res 2004; 78:347.</a></li><li><a class="nounderline abstract_t">Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J 1995; 21:221.</a></li><li><a class="nounderline abstract_t">Satitpitakul V, Kheirkhah A, Crnej A, et al. Determinants of Ocular Pain Severity in Patients With Dry Eye Disease. Am J Ophthalmol 2017; 179:198.</a></li><li><a class="nounderline abstract_t">Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea 2004; 23:272.</a></li><li><a class="nounderline abstract_t">Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004; 23:762.</a></li><li><a class="nounderline abstract_t">Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003; 44:4753.</a></li><li><a class="nounderline abstract_t">Montés-Micó R. Role of the tear film in the optical quality of the human eye. J Cataract Refract Surg 2007; 33:1631.</a></li><li><a class="nounderline abstract_t">Liu Z, Pflugfelder SC. Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology 1999; 106:939.</a></li><li><a class="nounderline abstract_t">The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:93.</a></li><li><a class="nounderline abstract_t">Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf 2017; 15:539.</a></li><li><a class="nounderline abstract_t">Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000; 118:615.</a></li><li><a class="nounderline abstract_t">Chalmers RL, Begley CG, Caffery B. Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): Discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses. Cont Lens Anterior Eye 2010; 33:55.</a></li><li><a class="nounderline abstract_t">Rajagopalan K, Abetz L, Mertzanis P, et al. Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye. Value Health 2005; 8:168.</a></li><li><a class="nounderline abstract_t">Rubin GS, West SK, Muñoz B, et al. A comprehensive assessment of visual impairment in a population of older Americans. The SEE Study. Salisbury Eye Evaluation Project. Invest Ophthalmol Vis Sci 1997; 38:557.</a></li><li><a class="nounderline abstract_t">Bentivoglio AR, Bressman SB, Cassetta E, et al. Analysis of blink rate patterns in normal subjects. Mov Disord 1997; 12:1028.</a></li><li><a class="nounderline abstract_t">Drugs for some common eye disorders. Treat Guidel Med Lett 2010; 8:1.</a></li><li><a class="nounderline abstract_t">Nilforoushan MR, Latkany RA, Speaker MG. Effect of artificial tears on visual acuity. Am J Ophthalmol 2005; 140:830.</a></li><li><a class="nounderline abstract_t">Laflamme MY, Swieca R. A comparative study of two preservative-free tear substitutes in the management of severe dry eye. Can J Ophthalmol 1988; 23:174.</a></li><li class="breakAll">Health Alert Network. Outbreak of extensively drug-resistant Pseudomonas aeruginosa associated with artificial tears. Centers for Disease Control and Prevention. Feb 1, 2023. Available at: https://emergency.cdc.gov/han/2023/han00485.asp (Accessed on February 02, 2023).</li><li><a class="nounderline abstract_t">Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf 2017; 15:575.</a></li><li><a class="nounderline abstract_t">Willen CM, McGwin G, Liu B, et al. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes. Eye Contact Lens 2008; 34:43.</a></li><li><a class="nounderline abstract_t">Huang FC, Tseng SH, Shih MH, Chen FK. Effect of artificial tears on corneal surface regularity, contrast sensitivity, and glare disability in dry eyes. Ophthalmology 2002; 109:1934.</a></li><li><a class="nounderline abstract_t">Bron AJ, Mangat H, Quinlan M, et al. Polyacrylic acid gel in patients with dry eyes: a randomised comparison with polyvinyl alcohol. Eur J Ophthalmol 1998; 8:81.</a></li><li><a class="nounderline abstract_t">Brodwall J, Alme G, Gedde-Dahl S, et al. A comparative study of polyacrylic acid (Viscotears) liquid gel versus polyvinylalcohol in the treatment of dry eyes. Acta Ophthalmol Scand 1997; 75:457.</a></li><li><a class="nounderline abstract_t">Lenton LM, Albietz JM. Effect of carmellose-based artificial tears on the ocular surface in eyes after laser in situ keratomileusis. J Refract Surg 1999; 15:S227.</a></li><li><a class="nounderline abstract_t">Sharma RA, Mather R. Five things to know about...dry eye disease. CMAJ 2014; 186:1090.</a></li><li><a class="nounderline abstract_t">Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011; 151:792.</a></li><li><a class="nounderline abstract_t">Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci 2010; 51:6125.</a></li><li><a class="nounderline abstract_t">Sambursky R, Davitt WF 3rd, Latkany R, et al. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol 2013; 131:24.</a></li><li><a class="nounderline abstract_t">Messmer EM, von Lindenfels V, Garbe A, Kampik A. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. Ophthalmology 2016; 123:2300.</a></li><li><a class="nounderline abstract_t">Sacchetti M, Mantelli F, Lambiase A, et al. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol 2014; 98:1016.</a></li><li><a class="nounderline abstract_t">de Paiva CS, Pflugfelder SC, Ng SM, Akpek EK. Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst Rev 2019; 9:CD010051.</a></li><li><a class="nounderline abstract_t">Akpek EK, Wirta DL, Downing JE, et al. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial. JAMA Ophthalmol 2023; 141:459.</a></li><li><a class="nounderline abstract_t">Malta JB, Soong HK, Shtein RM, et al. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea 2010; 29:1392.</a></li><li><a class="nounderline abstract_t">Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007; 114:76.</a></li><li><a class="nounderline abstract_t">Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. Cornea 2016; 35:741.</a></li><li><a class="nounderline abstract_t">Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology 2014; 121:475.</a></li><li><a class="nounderline abstract_t">Tauber J, Karpecki P, Latkany R, et al. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. Ophthalmology 2015; 122:2423.</a></li><li><a class="nounderline abstract_t">Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol 2012; 153:1050.</a></li><li><a class="nounderline abstract_t">Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). Ophthalmology 2017; 124:53.</a></li><li><a class="nounderline abstract_t">Wirta D, Vollmer P, Paauw J, et al. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial. Ophthalmology 2022; 129:379.</a></li><li><a class="nounderline abstract_t">Ballesteros-Sánchez A, De-Hita-Cantalejo C, Sánchez-González MC, et al. Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent. Ocul Surf 2023; 30:254.</a></li><li><a class="nounderline abstract_t">Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003; 136:593.</a></li><li><a class="nounderline abstract_t">Pinto-Fraga J, López-Miguel A, González-García MJ, et al. Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial. Ophthalmology 2016; 123:141.</a></li><li><a class="nounderline abstract_t">Ervin AM, Law A, Pucker AD. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2017; 6:CD006775.</a></li><li><a class="nounderline abstract_t">Noble BA, Loh RS, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol 2004; 88:647.</a></li><li><a class="nounderline abstract_t">Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface diseases. Br J Ophthalmol 2016; 100:22.</a></li><li><a class="nounderline abstract_t">Pan Q, Angelina A, Zambrano A, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev 2013; :CD009327.</a></li><li><a class="nounderline abstract_t">Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003; 62:1204.</a></li><li><a class="nounderline abstract_t">Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004; 23:784.</a></li><li><a class="nounderline abstract_t">Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye 2008; 31:141.</a></li><li><a class="nounderline abstract_t">Wojtowicz JC, Butovich I, Uchiyama E, et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea 2011; 30:308.</a></li><li><a class="nounderline abstract_t">Kangari H, Eftekhari MH, Sardari S, et al. Short-term consumption of oral omega-3 and dry eye syndrome. Ophthalmology 2013; 120:2191.</a></li><li><a class="nounderline abstract_t">Bhargava R, Kumar P. Oral omega-3 fatty acid treatment for dry eye in contact lens wearers. Cornea 2015; 34:413.</a></li><li><a class="nounderline abstract_t">Dry Eye Assessment and Management Study Research Group, Asbell PA, Maguire MG, et al. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. N Engl J Med 2018; 378:1681.</a></li><li><a class="nounderline abstract_t">Drouault-Holowacz S, Bieuvelet S, Burckel A, et al. Antioxidants intake and dry eye syndrome: a crossover, placebo-controlled, randomized trial. Eur J Ophthalmol 2009; 19:337.</a></li><li><a class="nounderline abstract_t">Blades KJ, Patel S, Aidoo KE. Oral antioxidant therapy for marginal dry eye. Eur J Clin Nutr 2001; 55:589.</a></li><li><a class="nounderline abstract_t">Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea 2007; 26:1195.</a></li><li><a class="nounderline abstract_t">Tseng KL, Liu HJ, Tso KY, et al. A clinical study of acupuncture and SSP (silver spike point) electro-therapy for dry eye syndrome. Am J Chin Med 2006; 34:197.</a></li><li><a class="nounderline abstract_t">Grönlund MA, Stenevi U, Lundeberg T. Acupuncture treatment in patients with keratoconjunctivitis sicca: a pilot study. Acta Ophthalmol Scand 2004; 82:283.</a></li><li><a class="nounderline abstract_t">Shigeyasu C, Hirano S, Akune Y, Yamada M. Diquafosol Tetrasodium Increases the Concentration of Mucin-like Substances in Tears of Healthy Human Subjects. Curr Eye Res 2015; 40:878.</a></li><li><a class="nounderline abstract_t">Gong L, Sun X, Ma Z, et al. A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore. Br J Ophthalmol 2015; 99:903.</a></li><li><a class="nounderline abstract_t">Yamaguchi M, Nishijima T, Shimazaki J, et al. Clinical usefulness of diquafosol for real-world dry eye patients: a prospective, open-label, non-interventional, observational study. Adv Ther 2014; 31:1169.</a></li><li><a class="nounderline abstract_t">Ueda K, Matsumiya W, Otsuka K, et al. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye. BMC Ophthalmol 2015; 15:58.</a></li><li><a class="nounderline abstract_t">Arimoto A, Kitagawa K, Mita N, et al. Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjögren syndrome patients with or without punctal occlusions. Cornea 2014; 33:806.</a></li><li><a class="nounderline abstract_t">Kinoshita S, Awamura S, Nakamichi N, et al. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. Am J Ophthalmol 2014; 157:576.</a></li></ol></div><div id="topicVersionRevision">Topic 6894 Version 58.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28736335" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : TFOS DEWS II Definition and Classification Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28736337" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : TFOS DEWS II Epidemiology Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28705660" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36301551" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence and Incidence of Dry Eye and Meibomian Gland Dysfunction in the United States: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388838" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17209665" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ocular adverse effects associated with systemic medications : recognition and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17534814" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ocular symptoms and signs with preserved and preservative-free glaucoma medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214564" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The diagnosis and management of dry eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18545008" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Dry eyes: etiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452369" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence, burden, and pharmacoeconomics of dry eye disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867401" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Utility assessment among patients with dry eye disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16900272" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Utility assessment to measure the impact of dry eye disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502474" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The economic burden of dry eye: a conceptual framework and preliminary assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9820935" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The pathology of dry eye: the interaction between the ocular surface and lacrimal glands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15106930" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Neural basis of sensation in intact and injured corneas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28736339" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : TFOS DEWS II pain and sensation report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557436" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20620090" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Elderly onset of primary Sjögren's syndrome: clinical manifestations, serological features and oral/ocular diagnostic tests. Comparison with adult and young onset of the disease in a cohort of 336 Italian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6331845" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17508116" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3766668" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A proposed mechanism for increased tear-film osmolarity in contact lens wearers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15767060" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Dry eye in diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9777650" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tear dynamics and dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15106912" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Functional aspects of the tear film lipid layer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565190" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28528121" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Determinants of Ocular Pain Severity in Patients With Dry Eye Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15084861" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The repeatability of clinical measurements of dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502475" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The lack of association between signs and symptoms in patients with dry eye disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578396" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17720082" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Role of the tear film in the optical quality of the human eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10328393" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17508117" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28736342" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : TFOS DEWS II Diagnostic Methodology report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10815152" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Reliability and validity of the Ocular Surface Disease Index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20093066" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): Discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15804325" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9071208" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A comprehensive assessment of visual impairment in a population of older Americans. The SEE Study. Salisbury Eye Evaluation Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399231" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Analysis of blink rate patterns in normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20032901" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Drugs for some common eye disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310460" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of artificial tears on visual acuity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3395921" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A comparative study of two preservative-free tear substitutes in the management of severe dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3395921" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A comparative study of two preservative-free tear substitutes in the management of severe dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28736343" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : TFOS DEWS II Management and Therapy Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180683" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12359618" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of artificial tears on corneal surface regularity, contrast sensitivity, and glare disability in dry eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9673476" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Polyacrylic acid gel in patients with dry eyes: a randomised comparison with polyvinyl alcohol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9374260" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A comparative study of polyacrylic acid (Viscotears) liquid gel versus polyvinylalcohol in the treatment of dry eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10202728" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of carmellose-based artificial tears on the ocular surface in eyes after laser in situ keratomileusis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24821862" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Five things to know about...dry eye disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310379" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Tear osmolarity in the diagnosis and management of dry eye disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20631232" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : An objective approach to dry eye disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23307206" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27665213" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24344232" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31517988" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Topical cyclosporine A therapy for dry eye syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37022717" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20847658" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17070588" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27055211" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24289915" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26365210" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22330307" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28079022" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34767866" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37813152" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14516798" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26520171" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28649802" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Punctal occlusion for dry eye syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15090417" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26178904" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Blood-derived topical therapy for ocular surface diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23982997" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Autologous serum eye drops for dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14644860" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502479" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18313350" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Oral omega-6 essential fatty acid treatment in contact lens associated dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21045648" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23642375" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Short-term consumption of oral omega-3 and dry eye syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25719253" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Oral omega-3 fatty acid treatment for dry eye in contact lens wearers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29652551" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19396775" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Antioxidants intake and dry eye syndrome: a crossover, placebo-controlled, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11464232" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Oral antioxidant therapy for marginal dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18043175" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16552832" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A clinical study of acupuncture and SSP (silver spike point) electro-therapy for dry eye syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15115449" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Acupuncture treatment in patients with keratoconjunctivitis sicca: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25310688" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Diquafosol Tetrasodium Increases the Concentration of Mucin-like Substances in Tears of Healthy Human Subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25631485" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25376447" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical usefulness of diquafosol for real-world dry eye patients: a prospective, open-label, non-interventional, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26048396" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24977983" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjögren syndrome patients with or without punctal occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24246575" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
